The Leadership Team extends our deepest ... welcomed a new partnership with Eli Lilly and Company. We also thank Lockheed Martin for being our steadfast partner for over a decade. Louise is an ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Is Eli Lilly a good stock to buy on the dip? On Jan. 14, CEO David Ricks told investors that 2024 sales would come in at ...

Eli Lilly is experiencing explosive growth ... recent acquisition from Scorpion really drive home the point that Lilly's management is thinking much farther into the future, well beyond where ...

For the last couple of years, the pharmaceutical sector has become infatuated with glucagon-like peptide 1 (GLP-1) agonists used to treat diabetes and help with chronic weight management.